TrialCurveGLOBE: reconstructed Kaplan–Meier curves
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Neuro Oncol. 2019 Dec 7;22(5):705–17. doi: 10.1093/neuonc/noz232 |
|---|---|
| DOI | 10.1093/neuonc/noz232 |
| Registry | NCT02511405 |
| Phase | Phase 3 |
| Conditions | Glioblastoma |
| Interventions | VB-111 + bevacizumab, Bevacizumab |
| Sponsor | Vascular Biogenics Ltd. operating as VBL Therapeutics |
| Enrolment | 252 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: BEVACIZUMAB 7.9 months; VB-111 + BEVACIZUMAB 6.6 months. Survival at 12 months: BEVACIZUMAB 25%; VB-111 + BEVACIZUMAB 25%. Hazard ratio BEVACIZUMAB vs VB-111 + BEVACIZUMAB 0.83 (95% CI 0.63–1.10).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| BEVACIZUMAB | 128 | 98 | 7.9 |
| VB-111 + BEVACIZUMAB | 128 | 106 | 6.6 |
- BEVACIZUMAB vs VB-111 + BEVACIZUMAB: reconstructed HR 0.83 (95% CI 0.63–1.10)
Landmark survival (reconstructed)
| Time | BEVACIZUMAB | VB-111 + BEVACIZUMAB |
|---|---|---|
| 6 mo | 69.5% | 55.5% |
| 12 mo | 24.7% | 25.2% |
| 18 mo | 11.8% | 6.4% |
| 24 mo | 11.8% | — |
Checks against the published figure
- BEVACIZUMAB median: printed 7.9, reconstructed 7.91 pass
- VB-111 + BEVACIZUMAB median: printed 6.8, reconstructed 6.61 pass
- hazard ratio (direction inferred): printed 1.2, reconstructed 1.2 pass
Progression-free survival
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: BEVACIZUMAB 3.8 months; VB-111 + BEVACIZUMAB 3.3 months. Survival at 12 months: BEVACIZUMAB 9%; VB-111 + BEVACIZUMAB 7%. Hazard ratio BEVACIZUMAB vs VB-111 + BEVACIZUMAB 0.76 (95% CI 0.58–0.98).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| BEVACIZUMAB | 128 | 104 | 3.8 |
| VB-111 + BEVACIZUMAB | 128 | 119 | 3.3 |
- BEVACIZUMAB vs VB-111 + BEVACIZUMAB: reconstructed HR 0.76 (95% CI 0.58–0.98)
Landmark survival (reconstructed)
| Time | BEVACIZUMAB | VB-111 + BEVACIZUMAB |
|---|---|---|
| 6 mo | 30.9% | 22.7% |
| 12 mo | 9.4% | 7.3% |
| 18 mo | 7.1% | — |
| 24 mo | 7.1% | — |
Checks against the published figure
- BEVACIZUMAB median: printed 3.7, reconstructed 3.81 pass
- VB-111 + BEVACIZUMAB median: printed 3.4, reconstructed 3.33 pass
- hazard ratio (direction inferred): printed 1.34, reconstructed 1.32 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/globe-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/globe-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Neuro Oncol. 2019 Dec 7;22(5):705–17. doi: 10.1093/neuonc/noz232 doi:10.1093/neuonc/noz232. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/globe
Report a problem with these data
Related trials
- Vebreltinib in PTPRZ1-MET fusion glioma: Overall survival; Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials